title: Funding crunch forces stem cell company to abandon therapies.
authors.forename: Monya
authors.initials: M
authors.lastname: Baker
mesh_terms: D064987:Cell- and Tissue-Based Therapy / Q000191:economics*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007449:Investments; D009938:Organizations / Q000191:economics*; D013234:Stem Cells